Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
AG

NASDAQ · AGMB

AgomAb Therapeutics N.V. American Depositary Shares

Healthcare · Biotechnology

$11.41

Down-$0.75 (-6.17%)

Updated Sep 17, 2026, 3:50 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
400.5K
P/E ratio
-10.62
Dividend yield
0.00%
52-week range
$8.75 – $17.82
Volume
120.33K
Avg. volume
382.73K

Price performance

AGMB price history

1M range · 20 trading sessions · Daily adjusted prices

AGMB closed at $11.41 after 20 trading sessions, down 17.02% for the selected period.

Last close
$11.41
Period change
-17.02%
Period low
$11.41
Period high
$15.78
Daily close
View OHLC price history
AGMB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$12.26$12.845$11.21$11.41120.33K
Sep 15, 2026$12.31$12.915$11.61$12.16146.34K
Sep 14, 2026$13.20$13.29$12.20$12.2886.19K
Sep 11, 2026$14.00$14.10$12.96$13.06196.65K
Sep 10, 2026$14.91$16.40$13.75$13.94106.93K
Sep 9, 2026$14.94$15.70$14.645$14.9672.56K
Sep 8, 2026$15.78$16.50$14.51$14.91260.63K
Sep 4, 2026$14.83$15.86$14.53$15.78245.27K
Sep 3, 2026$13.67$14.94$13.5856$14.83407.96K
Sep 2, 2026$13.29$13.955$13.19$13.66158.85K
Sep 1, 2026$12.90$13.99$12.62$13.54241.31K
Aug 31, 2026$13.15$14.13$12.75$13.17105.44K
Aug 28, 2026$13.84$14.20$12.84$13.17252.92K
Aug 27, 2026$14.26$14.37$13.66$13.84154.17K
Aug 26, 2026$14.19$14.60$13.58$14.28243.8K
Aug 25, 2026$13.40$14.26$13.16$14.02219.35K
Aug 24, 2026$13.21$13.23$12.755$12.8231.65K
Aug 21, 2026$13.50$13.64$13.065$13.2568.36K
Aug 20, 2026$13.74$13.85$13.01$13.4392.23K
Aug 19, 2026$13.81$14.42$13.59$13.75137.39K

Latest AGMB news

The latest Smart Investors Daily articles mentioning AGMB.

Stock researchCompany · Overview

AGMB research

Overview

Company profile and research snapshot.

Company profile

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
AGMB recent ratings
DateFirmRatingTarget
Aug 25, 2026Piper SandlerOverweight—
Aug 19, 2026Cantor FitzgeraldOverweight—
Jul 23, 2026B. Riley SecuritiesBuy—
Jun 22, 2026HC Wainwright & Co.Buy—
Mar 3, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 11, 2026

Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Antwerp, Belgium, September 11, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that shareholders approved all resolutions submitted for consideration at the Company's Special and Extraordinary General Shareholders' Meeting held on September 11, 2026. The approved resolutions included the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the

Yahoo · Aug 10, 2026

Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Antwerp, Belgium, August 10, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company's Special General Meeting to be held on September 11, 2026. “We are deli

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By